Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Large Increase in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 53,600 shares, an increase of 26.7% from the February 28th total of 42,300 shares. Approximately 2.9% of the shares of the company are short sold. Based on an average trading volume of 66,000 shares, the days-to-cover ratio is currently 0.8 days.

Lixte Biotechnology Stock Up 2.1 %

NASDAQ LIXT opened at $1.22 on Thursday. The company has a market cap of $3.27 million, a PE ratio of -0.71 and a beta of 0.19. Lixte Biotechnology has a 52 week low of $1.02 and a 52 week high of $3.80. The firm’s 50-day simple moving average is $1.62 and its two-hundred day simple moving average is $1.85.

Lixte Biotechnology (NASDAQ:LIXT) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.27) EPS for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

An institutional investor recently bought a new position in Lixte Biotechnology stock. TIAA Trust National Association acquired a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 101,834 shares of the company’s stock, valued at approximately $207,000. TIAA Trust National Association owned approximately 4.53% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission. 5.10% of the stock is currently owned by institutional investors and hedge funds.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.